Results 1 to 10 of about 47,439 (299)

PRF1 is a prognostic marker and correlated with immune infiltration in head and neck squamous cell carcinoma

Translational Oncology, 2021
Purpose: Head and neck squamous cell carcinoma (HNSCC) is a highly invasive malignancy with poor survival. Perforin (PRF1) plays essential roles in host immunity.
Cui Fan, Haixia Hu, Yilin Shen, Quan Wang, Yufeng Mao, Bin Ye, Mingliang Xiang   +6 more
doaj   +1 more source

Machine learning with the TCGA-HNSC dataset: improving usability by addressing inconsistency, sparsity, and high-dimensionality

BMC Bioinformatics, 2019
Background In the era of precision oncology and publicly available datasets, the amount of information available for each patient case has dramatically increased.
Michael C. Rendleman, John M. Buatti, Terry A. Braun, Brian J. Smith, Chibuzo Nwakama, Reinhard R. Beichel, Bart Brown, Thomas L. Casavant   +7 more
doaj   +1 more source

Medical Gas Plasma Treatment in Head and Neck Cancer—Challenges and Opportunities

Applied Sciences, 2020
Despite progress in oncotherapy, cancer is still among the deadliest diseases in the Western world, emphasizing the demand for novel treatment avenues.
Julia Berner, Christian Seebauer, Sanjeev Kumar Sagwal, Lars Boeckmann, Steffen Emmert, Hans-Robert Metelmann, Sander Bekeschus   +6 more
doaj   +1 more source

Relevance of Neurotrophin Receptors CD271 and TrkC for Prognosis, Migration, and Proliferation in Head and Neck Squamous Cell Carcinoma

Cells, 2019
Head and neck squamous cell carcinoma (HNSCC) is the sixth most common cancer worldwide and often has a poor prognosis. The present study investigated the role of the low affinity nerve growth factor receptor CD271 as a putative therapy target in HNSCC ...
Yannick Foerster, Timo Stöver, Jens Wagenblast, Marc Diensthuber, Sven Balster, Jennis Gabrielpillai, Hannah Petzold, Christin Geissler   +7 more
doaj   +1 more source

CD44v3 protein-carrying tumor-derived exosomes in HNSCC patients’ plasma as potential noninvasive biomarkers of disease activity

OncoImmunology, 2020
The molecular cargo of tumor-cell-derived exosomes (TEX) mimics that of parental tumor cells. Thus, TEX could potentially serve as noninvasive biomarkers of cancer progression.
Marie-Nicole Theodoraki, Akihiro Matsumoto, Inga Beccard, Thomas K. Hoffmann, Theresa L. Whiteside   +4 more
doaj   +1 more source

Roles of E2F family members in the diagnosis and prognosis of head and neck squamous cell carcinoma

BMC Medical Genomics, 2023
Background Head and neck squamous cell carcinoma (HNSCC) is the sixth most prevalent cancer worldwide. E2Fs are a group of transcription factors involved in the carcinogenesis and progression of various cancers. However, the exact roles of each member of
Yaoxu Li, Yinpei Huang, Bing Li, Kai Yang   +3 more
doaj   +1 more source

T-helper and T-regulatory cells modulation in head and neck squamous cell carcinoma

OncoImmunology, 2017
Head and neck squamous cell carcinoma (HNSCC) is one of the most diffused cancer types, characterized by a high reoccurrence rate, mainly due to the inability of current therapeutic approaches to completely eradicate cancer cells.
Daniele Maggioni, Lorenzo Pignataro, Werner Garavello   +2 more
doaj   +1 more source

The landscape of CD28, CD80, CD86, CTLA4, and ICOS DNA methylation in head and neck squamous cell carcinomas

Epigenetics, 2020
CTLA-4 blocking therapeutic antibodies are currently under investigation in head and neck squamous cell carcinoma (HNSCC). A better understanding of the epigenetic regulation of the CD28 superfamily members CD28, CTLA-4, and ICOS and their B7 ligands ...
Luka de Vos, Ingela Grünwald, Emma Grace Bawden, Jörn Dietrich, Kathrin Scheckenbach, Constanze Wiek, Romina Zarbl, Friedrich Bootz, Jennifer Landsberg, Dimo Dietrich   +9 more
doaj   +1 more source

Prognosis-related molecular subtyping in head and neck squamous cell carcinoma patients based on glycolytic/cholesterogenic gene data

Cancer Cell International, 2023
Background Head and neck squamous cell carcinoma (HNSCC) remains an unmet medical challenge. Metabolic reprogramming is a hallmark of diverse cancers, including HNSCC.
Zekun Zhou, Jianfei Tang, Yixuan Lu, Jia Jia, Tiao Luo, Kaixin Su, Xiaohan Dai, Haixia Zhang, Ousheng Liu   +8 more
doaj   +1 more source

HPV and CSC in HNSCC cisplatin resistance

Frontiers in Bioscience, 2015
Cisplatin (DNA intercalator), a standard chemotherapy drug often used to treat head and neck squamous cellular carcinoma (HNSCC) has very low response rates in recurrent disease of HNSCC, this is a major clinical problem today. However, a valuable window to look in to the underlying molecular aspects of a favorable and unfavorable cisplatin response is
Vishnu, Modur, K, Thomas-Robbins, Krishna, Rao   +2 more
openaire   +2 more sources